VEGF Human

VEGF Human

  • Name
  • Description
  • Cat#
  • Pricings
  • Quantity
  • VEGF Human

  • Vascular Endothelial Growth Factor Human Recombinant
  • CYT-241
  • Shipped at Room temp.

Catalogue number



Vascular endothelial growth factor A, VEGF-A, Vascular permeability factor, VPF, VEGF, MGC70609.


Vascular endothelial growth factor (VEGF) is an important signaling protein involved in vessel formation As its name implies, VEGF activity has been mostly studied on cells of the vascular endothelium, although it does have effects on a number of other cell types (e.g. stimulation monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells ). VEGF mediates increased vascular permeability, induces vasculogenesis and endothelial cell production, promotes cell migration, and inhibits apoptosis. In vitro, VEGF has been shown to stimulate endothelial cell mitogenesis and cell migration. VEGF is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor. VEGF is located in normal cartilage though only osteoarthritic cartilage expresses the VEGF receptors, NP1, VEGFR1 and VEGFR2. The VEGF level in the culture media from OA chondrocytes was more than 3 folds higher than in media from normal chondrocytes


Vascular Endothelial Growth Factor Human Recombinant produced in E.Coli is a double, non-glycosylated, polypeptide chain containing 165 amino acids and having a molecular mass of 38.2kDa.
The VEGF is purified by proprietary chromatographic techniques.


Escherichia Coli.

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.


The VEGF protein was lyophilized from a concentrated (1mg/ml) solution with no additives.


It is recommended to reconstitute the lyophilized VEGF in sterile 18M-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.


Lyophilized VEGF although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution VEGF should be stored at 4°C between 2-7 days and for future use below -18°C.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please prevent freeze-thaw cycles.


Greater than 95.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.

Amino acid sequence


Biological Activity

Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 3.7-5.6 ng/ml, corresponding to a Specific Activity of 178,570-270,270IU/mg.

Protein content

VEGF protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280 nm using the absorbency value of 0.2875 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).
2. Analysis by RP-HPLC, using a calibrated solution of VEGF as a Reference Standard.


Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Safety Data Sheet


1. Title:Expression of VEGF and Its Receptors in the Bovine Endometrium Throughout the Estrous Cycle: Effects of VEGF on Prostaglandin Production in Endometrial Cells.
Publication:Journal of Reproduction and Development
Vol. 56 (2010) No. 2 April P 223-229 \
Link:VEGF prospec publication

2. Title: Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors
Publications:  Gene therapy 15.1 (2008): 12-17.
Link: VEGF Human prospec publication


3. Title: SU11248, A selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells
Publication:   Cancer biology & therapy 10.7 (2010): 703-711.
Link: Vascular Endothelial Growth Factor prospec publication



VEGF (Vascular Endothelial Growth Factor) Human Recombinant: Exploring Its Angiogenic Potential and Therapeutic Applications



VEGF (Vascular Endothelial Growth Factor), also known as VPF, VEGF, or MGC70609, is a critical signaling protein involved in angiogenesis and vascular development.


This research paper aims to provide a comprehensive analysis of the molecular characteristics, signaling pathways, and diverse functions of VEGF.


Additionally, it explores the therapeutic implications of VEGF in various diseases. Synonyms such as VPF, VEGF, and MGC70609 associated with the protein are discussed throughout the paper to highlight their relevance in scientific literature.



1. VEGF, also known as VPF, VEGF, or MGC70609, is a key angiogenic factor with significant implications in vascular development and disease. This section introduces VEGF and its synonyms, emphasizing their importance and relevance in scientific research.


Molecular Characteristics of VEGF:

2. This section explores the molecular characteristics of VEGF, including its primary amino acid sequence, protein structure, and isoforms. The post-translational modifications and binding partners involved in VEGF signaling are discussed, highlighting their impact on VEGF's biological activity.


Signaling Pathways Activated by VEGF:

3. VEGF activates specific signaling pathways upon binding to its receptors, leading to endothelial cell proliferation, migration, and angiogenesis. This section focuses on the activation of the VEGFR-2 pathway and downstream effectors involved in mediating VEGF's angiogenic effects.


Physiological Functions of VEGF:

4. VEGF plays critical roles in various physiological processes, including embryonic development, tissue repair, and wound healing. This section provides an in-depth analysis of VEGF's contributions to these processes, emphasizing its role in promoting angiogenesis, vascular permeability, and endothelial cell survival.


Therapeutic Implications of VEGF:

5. The angiogenic properties of VEGF have led to its potential therapeutic applications in various diseases. This section discusses the therapeutic strategies targeting VEGF in cancer, ischemic diseases, and ocular disorders. The challenges and considerations in manipulating VEGF for therapeutic purposes are also addressed.


VEGF in Disease Pathogenesis:

6. VEGF dysregulation is implicated in the pathogenesis of several diseases, including cancer, diabetic retinopathy, and cardiovascular disorders. This section examines the role of VEGF in disease progression, highlighting its contribution to angiogenesis, neovascularization, and vascular permeability. The therapeutic approaches targeting VEGF in specific diseases are also discussed.



7. VEGF, also known as VPF, VEGF, or MGC70609, is a critical mediator of angiogenesis and vascular development. Understanding the molecular characteristics, signaling pathways, and physiological functions of VEGF contributes to the exploration of its therapeutic potential in various diseases

Back to Top